The Cabinet Committee on Economic Affairs (CCEA) has approved foreign investments in Aurobindo Pharma. The approval has been given for Qualified Institutional Buyers (QIBs) to infuse fresh equity of up to 7% amounting to about Rs 2,165 crore into the company. The existing FII shareholding is 27.32% in the company.
This will enable the company to expand its operations in the areas of anti infective, cardiovascular and central nervous system related ingredients. The company employs more than 9500 professionals from 26 countries.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
